EquityFlowCompanies › Rhelixa

Rhelixa

Biotech · Tokyo, JP

Epigenetic-clock biological-age assessment and anti-aging (Epiclock)

Funding history

DateRoundAmount
Aug 2024Series B
Rhelixa, an epigenetics anti-aging startup, raised 490M JPY in Series B from Daiwa Corporate Investment, the KIRIN Health Innovation Fund and Leave a Nest Capital (incl. loans), taking cumulative funding to 1.28B JPY.
$3.2M

Investors

Daiwa Corporate InvestmentKirin Health Innovation FundLeave a Nest Capital

Similar companies in Biotech

Explore funding flow on EquityFlow →